Fulgent Genetics (FLGT) Earnings Transcript

Core Insights - The company has made significant progress in its laboratory services and therapeutic development business, with a focus on digital pathology and AI technology, which are expected to enhance efficiency and throughput [6][12][20] - The company anticipates a transition period in 2026 due to a major customer moving testing in-house, which will impact revenue but is expected to be offset by strategic acquisitions [7][26][27] - The company is actively pursuing acquisitions to strengthen its laboratory services and expand its client base, with a notable acquisition of Bako Diagnostics and StrataDx planned [15][16][25] Financial Performance - For the fourth quarter of 2025, total revenue was $83.3 million, a 9% increase year-over-year, while full-year revenue reached $322.7 million, up approximately 14% from 2024 [14][21] - The gross margin for Q4 2025 was 41% on a non-GAAP basis and 39.1% on a GAAP basis, with full-year gross margins improving due to operational efficiencies [21][22] - Non-GAAP operating expenses for Q4 were $43.1 million, reflecting an increase due to acquisition-related costs and other expenses [22] Strategic Initiatives - The company launched new products in 2025, including RNA-integrated whole genome sequencing, which contributed to revenue growth [7][8] - The therapeutic development pipeline is progressing, with clinical candidates FID-7 and FID-22 advancing through trials, with FID-7 showing promising early efficacy [8][10][11] - The company is investing in AI and digital pathology solutions, which are expected to enhance service efficiency and precision [12][19] Customer Dynamics - The largest customer accounted for $70.8 million in revenue in 2025, but this is expected to decline significantly in 2026 as they transition testing in-house [26][35] - The company plans to mitigate the revenue loss by leveraging the anticipated contributions from the Bako and StrataDx acquisitions, which are expected to generate approximately $50 million to $55 million in revenue [27][36] Future Outlook - The company forecasts total revenues of approximately $350 million for 2026, representing an 8.5% year-over-year growth, with a strong pipeline for customer opportunities in Precision Diagnostics [27][30] - Non-GAAP gross margins are expected to be slightly above 40% for the full year 2026, with anticipated lower margins in the first half due to the impact of the largest customer's transition [28][29] - The company is committed to maintaining a strong cash position, with expectations to end 2026 with approximately $606 million to $685 million in cash and equivalents [31][59]